Enzymatica AB (FRA:EN9) Other Stockholders Equity: €10.30 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EN9 Enzymatica AB FRA:EN9
43 GF Score
Price €0.19
GF Value €0.16
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Enzymatica AB Other Stockholders Equity?

Enzymatica AB FRA:EN9 -0.77% 43 Other Stockholders Equity is €10.30 Mil as of Mar. 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 43/100 and a GF Value™ of €0.16 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Enzymatica AB's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €10.30 Mil.

Enzymatica AB's quarterly Other Stockholders Equity declined from Sep. 2025 (€12.33 Mil) to Dec. 2025 (€0.06 Mil) but then increased from Dec. 2025 (€0.06 Mil) to Mar. 2026 (€10.30 Mil).

Enzymatica AB's annual Other Stockholders Equity increased from Dec. 2023 (€0.02 Mil) to Dec. 2024 (€0.11 Mil) but then declined from Dec. 2024 (€0.11 Mil) to Dec. 2025 (€0.06 Mil).

Enzymatica AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Other Stockholders Equity Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.08 0.02 0.02 0.11 0.06

Enzymatica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.42 13.05 12.33 0.06 10.30
FRA:EN9
43GF Score
Enzymatica AB FRA:EN9
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enzymatica AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €10.30 Mil mean?
Enzymatica AB (FRA:EN9) has a Other Stockholders Equity of €10.30 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Enzymatica AB and its competitors.
Is Enzymatica AB's Other Stockholders Equity too high?
Enzymatica AB's current Other Stockholders Equity is €10.30 Mil. Overall, Enzymatica AB has a GF Score™ of 43/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Other Stockholders Equity compare to ZTS and UTHR?
Enzymatica AB's Other Stockholders Equity of €10.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current Other Stockholders Equity is €10.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.16, compared to a current price of €0.19 — trading 21.3% above its estimated fair value. The current Other Stockholders Equity is €10.30 Mil. Enzymatica AB's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Other Stockholders Equity is €10.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be overvalued. The current stock price of €0.19 is trading 21.3% above its estimated GF Value™ of €0.16. GuruFocus considers Enzymatica AB to be Modestly Overvalued.

Key valuation signals for FRA:EN9:

  • Other Stockholders Equity: €10.30 Mil
  • GF Value™: €0.16 vs. price of €0.19 (21.3% above fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
43GF Score

Get the complete analysis for FRA:EN9

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€0.16
GF Value